• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil
Oral anticoagulation (OA) is a well-established therapeutic approach for prevention of cardioembolic stroke and venous thromboembolism [1]. Adequate OA is a key element in reducing the high social burden, morbidity and mortality associated with cardiovascular diseases [2 –4]. In January 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern. Since then, the strategy of social distancing has been adopted in most countries, with varying degrees of restriction and compliance.
Source: Thrombosis Research - July 9, 2021 Category: Hematology Authors: Kendra Lys Calixto Machado, Suzana Tanquella da Rosa, Soraya Dobner, Ivan Schneider Boettcher, Gilberto Comaru Pasqualotto, Adelina Elisabeth Lehmkuhl Lopes, Tain á de Araújo, Lysandra Patricia Luchtenberg Bolduan, Maria Daniela Holthausen Perico Colomb Tags: Letter to the Editors-in-Chief Source Type: research

Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research

5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry
Following successful phase-III trials, direct oral anticoagulants such as rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF). However, data from randomized trials should be confirmed in unselected cohorts.
Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: Luise Tittl, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf Tags: Full Length Article Source Type: research

Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant
Atrial fibrillation (AF) is associated with increased risk of stroke and thromboembolism. Patients with AF have a higher incidence of renal impairment, which may influence the risks of systemic thromboembolism or bleeding. We determined how different oral anticoagulants affect plasma clot properties and whether progressive renal dysfunction affects plasma clot properties in patients on warfarin.
Source: Thrombosis Research - November 7, 2020 Category: Hematology Authors: Ahsan A. Khan, Lewis J. Hardy, Eduard Shantsila, Yee C. Lau, Helen Philippou, Gregory Y.H. Lip Source Type: research

Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis
To recommend the proper anticoagulant drug and its dose for patients with atrial fibrillation (AF) and heart failure (HF), we conducted a network meta-analysis (NMA) to make the comparisons among non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin with regard to efficacy (stroke or systemic embolism) and safety (major bleeding).
Source: Thrombosis Research - August 12, 2020 Category: Hematology Authors: Hao Jin, Kongbo Zhu, Lina Wang, Wangjuan Zhou, Hong Zhi Tags: Review Article Source Type: research

Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand
Novel oral anticoagulants (NOACs) and warfarin care bundles (e.g. genotyping, patient self-testing or self-management) are alternatives to usual warfarin care for stroke prevention in patients with atrial fibrillation (AF). We aim to evaluate the cost-effectiveness of NOACs and warfarin care bundles in patients with AF in a middle-income country, Thailand.
Source: Thrombosis Research - November 14, 2019 Category: Hematology Authors: Siok Shen Ng, Surakit Nathisuwan, Arintaya Phrommintikul, Nathorn Chaiyakunapruk Tags: Full Length Article Source Type: research

Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and rivaroxaban in atrial fibrillation
Direct oral anticoagulants (DOACs) have been proven non-inferior or superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major hemorrhage, in patients with non-valvular atrial fibrillation (NVAF). We sought to investigate whether effectiveness and safety differs among apixaban, rivaroxaban and dabigatran.
Source: Thrombosis Research - November 12, 2019 Category: Hematology Authors: M. Jansson, S. Sj älander, V. Sjögren, H. Renlund, B. Norrving, A. Själander Tags: Full Length Article Source Type: research

Oral anticoagulant-associated bleeding requiring hospitalization in Thai patients: Incidences, risk factors, and outcomes
Oral anticoagulants have been widely used in patients with atrial fibrillation (AF), mechanical valve and in the treatment of both arterial and venous thromboembolism (VTE). Warfarin is the conventional oral anticoagulant which was established its efficacy and safety profiles. Direct oral anticoagulants (DOACs) including dabigatran, rivaroxaban, and apixaban, have gained their popularity and been increasingly used since their approval in Thailand for stroke prevention in AF and VTE treatment.
Source: Thrombosis Research - September 4, 2019 Category: Hematology Authors: Kochawan Boonyawat, Patratorn Kunakorntham, Pantep Angchaisuksiri Tags: Letter to the Editors-in-Chief Source Type: research

Outcomes of direct oral anticoagulant- and warfarin-associated hemorrhage: A single center retrospective cohort study
Direct oral anticoagulants (DOACs) are now a mainstay of anticoagulant therapy for the prevention and treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (a-fib). However, bleeding-related morbidity and mortality remains a feared complication. Bleeding in patients taking DOACs in clinical trials showed comparable, if not more favorable, outcomes compared to that of warfarin [1 –4]. However, the safety of DOAC use should also be evaluated in less selected cohorts in the real-world.
Source: Thrombosis Research - September 2, 2019 Category: Hematology Authors: Lorraine Cafuir, En Cheng, Christine Kempton Tags: Letter to the Editors-in-Chief Source Type: research

The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
Factor (F) Xa inhibitors are safe and effective alternatives to warfarin in the treatment of venous thrombosis and as stroke prophylaxis in patients with non-valvular atrial fibrillation. Even though the risk of major bleeding is lower for FXa inhibitors than warfarin in general, FXa inhibitors have been reported to cause a different bleeding profile. Inhibition of FXa by rivaroxaban is associated with more gastrointestinal bleeds and heavy uterine bleedings [1 –3] than warfarin. Also, low-dose rivaroxaban has been shown to reduce major ischemic outcomes and death after acute coronary events [4].
Source: Thrombosis Research - March 12, 2019 Category: Hematology Authors: Nina Haagenrud Schultz, P ål Andre Holme, Carola Elisabeth Henriksson, Marie-Christine Mowinckel, Per Morten Sandset, Vibeke Bratseth, Eva-Marie Jacobsen Tags: Letter to the Editors-in-Chief Source Type: research

Apixaban and rivaroxaban in patients with cerebral venous thrombosis
Cerebral venous thrombosis (CVT) affects approximately 15 people per million annually and represents 0.5% of all stroke [1,2]. Initiation of anticoagulation with heparin followed by warfarin is currently the standard of care, after confirmation of diagnosis with computed tomography (CT) or magnetic resonance (MR) venography [3]. Apixaban and rivaroxaban have been shown to be non-inferior to warfarin for the treatment of deep vein thrombosis and pulmonary embolism [4,5]. However, only case reports and small case series have described their use in patients with CVT.
Source: Thrombosis Research - November 20, 2018 Category: Hematology Authors: Fahrettin Covut, Tariq Kewan, Oscar Perez, Monica Flores, Abdo Haddad, Hamed Daw Tags: Letter to the Editors-in-Chief Source Type: research

6. Abstract Title: Thrombotic and Bleeding Outcomes Following Perioperative Interruption of DOACs and VKAs in Patients with Non-Valvular Atrial Fibrillation - A Comparative Analysis
Background: Atrial fibrillation (AF) is a common disorder that will affect up to 5.6 million patients in the U.S. by 2050. Both direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), typically warfarin, are used for stroke prevention in AF and such patients frequently undergo invasive procedures, requiring anticoagulant interruption. Temporary interruption of anticoagulants can be associated with significant morbidity and mortality in the form of thromboembolic and bleeding complications.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Joseph Shaw, Tinghua Zhang, Gregoire Le Gal, James Douketis, Marc Carrier Source Type: research

Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study
The non-vitamin K oral antagonists (NOACs) are at least as effective as warfarin in the prevention of stroke in non valvular atrial fibrillation (NVAF) and are associated with less intracranial hemorrhage. Many patients with NVAF inappropriately do not receive anticoagulants often because of the inconvenience associated with warfarin administration. NOACs have the potential to increase anticoagulation use because they are safer and easier to administer than warfarin. Indeed, the use of anticoagulation in patients with newly diagnosed AF in many countries is increasing as a result of the use of NOACs in preference to warfarin [1].
Source: Thrombosis Research - July 24, 2018 Category: Hematology Authors: Martin H. Ellis, Sari Greenberg Dotan, Ariel Hammerman, Erez Battat, Estela Derazne, Orly Avnery Tags: Letter to the Editors-in-Chief Source Type: research

Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
New oral anticoagulants are non-inferior compared with warfarin regarding stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is unclear whether high TTR warfarin is as effective and safe as NOACs. Our objective was to investigate efficacy and safety of apixaban, dabigatran or rivaroxaban compared with warfarin in clinical practice.
Source: Thrombosis Research - May 17, 2018 Category: Hematology Authors: Sara Sj älander, Vilhelm Sjögren, Henrik Renlund, Bo Norrving, Anders Själander Tags: Full Length Article Source Type: research

Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization
Dabigatran etexilate (DE), a new oral anti-coagulant, is a direct thrombin inhibitor. Clinical trials showed the favorable benefit-to-risk profile of DE compared to warfarin for the prevention of ischemic stroke in patients with atrial fibrillation. Remarkably, patients treated with dabigatran showed reduced rates of intracerebral hemorrhage compared to warfarin. As the breakdown of endothelial barrier integrity is associated with hemorrhagic events and as thrombin increases endothelial permeability, we hypothesized that dabigatran preserves the endothelial barrier by inhibiting thrombin-induced permeability.
Source: Thrombosis Research - April 25, 2018 Category: Hematology Authors: Hyun-Jung Choi, Na-Eun Kim, Jayoung Kim, Sunho An, Seung-Hee Yang, Jimin Ha, Sunghee Cho, Il Kwon, Young Dae Kim, Hyo Suk Nam, Ji Hoe Heo Tags: Full Length Article Source Type: research

Pages: 1  2  3